|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15431544154515461547154815491550155115521553...15771578» |
- New P1 trial: TAA-Specific CTLS for Solid Tumors (TACTASOM) (clinicaltrials.gov) - Sep 15, 2014
P1, N=18, Not yet recruiting, Sponsor: Baylor College of Medicine
- adavosertib (AZD1775) / AstraZeneca
Enrollment open, Combination therapy, Monotherapy: NCI-2014-00620: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Sep 15, 2014
P2, N=100, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting
- temozolomide / Generic mfg.
Enrollment closed: Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Sep 15, 2014
P=N/A, N=10, Active, not recruiting, Sponsor: Mayo Clinic
Suspended --> Recruiting Recruiting --> Active, not recruiting
- || CC-115 / BMS
Trial primary completion date, Metastases: Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. (clinicaltrials.gov) - Sep 12, 2014
P1, N=144, Recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Jul 2015
- || Fragmin (dalteparin sodium) / Pfizer, Eisai
Trial primary completion date: Dalteparin in Preventing DVT in Participants With Cancer (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Jul 2015 --> Jul 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma (clinicaltrials.gov) - Sep 12, 2014
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- ||| ontuxizumab (MORAb-004) / Eisai
Enrollment closed, Metastases: Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation (clinicaltrials.gov) - Sep 12, 2014
P2, N=200, Active, not recruiting, Sponsor: Morphotek
Trial primary completion date: Aug 2015 --> Aug 2016 Recruiting --> Active, not recruiting
- Recentin (cediranib) / AstraZeneca
Trial primary completion date: Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Sep 11, 2014
P2, N=73, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2016 --> Jul 2015
- Ogsiveo (nirogacestat) / SpringWorks Therap
Enrollment closed, Trial primary completion date: Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis (clinicaltrials.gov) - Sep 11, 2014
P2, N=17, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2016 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Dec 2016
- Kisqali (ribociclib) / Novartis
Enrollment closed, Enrollment change, Trial primary completion date: Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma (clinicaltrials.gov) - Sep 11, 2014
P1, N=32, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Dec 2016 Recruiting --> Active, not recruiting | N=64 --> 32 | Trial primary completion date: May 2015 --> Dec 2014
- | aldoxorubicin (INNO-206) / ImmunityBio
New P1/2 trial, Metastases: Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 10, 2014
P1/2, N=30, Recruiting, Sponsor: CytRx
- | Sutent (sunitinib) / Pfizer
Phase classification, Stroma: Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=600, Enrolling by invitation, Sponsor: Pfizer
Recruiting --> Active, not recruiting | N=64 --> 32 | Trial primary completion date: May 2015 --> Dec 2014 Phase classification: P4 --> P=N/A
- | Sutent (sunitinib) / Pfizer
Phase classification: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=600, Enrolling by invitation, Sponsor: Pfizer
Phase classification: P4 --> P=N/A Phase classification: P4 --> P=N/A
- temozolomide / Generic mfg., memantine / Generic mfg., mefloquine / Generic mfg.
Trial primary completion date: Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy (clinicaltrials.gov) - Sep 9, 2014
P1, N=144, Recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P4 --> P=N/A Trial primary completion date: Sep 2015 --> Sep 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Sep 9, 2014
P2, N=70, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Jun 2014 --> Oct 2013
- |||| Trial primary completion date, IO biomarker, Surgery: ARST0332: Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 9, 2014
P3, N=588, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jun 2014 --> Oct 2013 Trial primary completion date: Feb 2012 --> Sep 2014
- H1299 cell lysate with iscomatrix adjuvant vaccine / National Cancer Institute
Enrollment open, IO biomarker: Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (clinicaltrials.gov) - Sep 9, 2014
P1/2, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2012 --> Sep 2014 Active, not recruiting --> Recruiting
- Trial completion, Enrollment change, Trial primary completion date: Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer (clinicaltrials.gov) - Sep 9, 2014
P2, N=101, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=180 --> 101 | Trial primary completion date: Jul 2009 --> Feb 2013
- Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Stereotactic Radiation Therapy for Pediatric Sarcomas (clinicaltrials.gov) - Sep 8, 2014
P2, N=20, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed | N=180 --> 101 | Trial primary completion date: Jul 2009 --> Feb 2013 Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Nov 2013 | Trial primary completion date: Jul 2017 --> Nov 2017
- | Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: DIPG: Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Sep 8, 2014
P1/2, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Nov 2013 | Trial primary completion date: Jul 2017 --> Nov 2017 Suspended --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change: Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Sep 8, 2014
P1/2, N=144, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting N=51 --> 144
- Enrollment open, IO biomarker: Molecular-Guided Therapy for Childhood Cancer (clinicaltrials.gov) - Sep 8, 2014
P=N/A, N=56, Recruiting, Sponsor: Giselle Sholler
N=51 --> 144 Not yet recruiting --> Recruiting
- Halaven (eribulin mesylate) / Eisai
Enrollment open, Trial initiation date: AOST1322: Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Sep 8, 2014
P2, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014
- M032 / The University of Alabama
Enrollment open: M032-HSV-1: Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (clinicaltrials.gov) - Sep 8, 2014
P1, N=36, Recruiting, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- |||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Trial completion, Metastases: A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer (clinicaltrials.gov) - Sep 6, 2014
P2, N=271, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment open, Metastases: Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy (clinicaltrials.gov) - Sep 5, 2014
P2, N=36, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- imatinib / Generic mfg.
Trial primary completion date: Basket 1: Imatinib in Patients With Desmoid Tumor and Chondrosarcoma (clinicaltrials.gov) - Sep 5, 2014
P2, N=35, Recruiting, Sponsor: Italian Sarcoma Group
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2013 --> Sep 2014
- Trial primary completion date: Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=750, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Sep 2013 --> Sep 2014 Trial primary completion date: Aug 2014 --> Aug 2015
- || carotuximab IV (ENV-105) / Kairos Pharma
Enrollment change, Trial primary completion date, Combination therapy, Metastases: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 5, 2014
P1b, N=81, Recruiting, Sponsor: Tracon Pharmaceuticals Inc.
Trial primary completion date: Aug 2014 --> Aug 2015 N=18 --> 81 | Trial primary completion date: Apr 2014 --> Mar 2015
- Recentin (cediranib) / AstraZeneca
Enrollment change, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Sep 5, 2014
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
N=18 --> 81 | Trial primary completion date: Apr 2014 --> Mar 2015 N=47 --> 70
- | amcasertib (BBI-503) / Sumitomo Pharma
New P2 trial, Stroma, Metastases: A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Sep 5, 2014
P2, N=30, Not yet recruiting, Sponsor: Boston Biomedical, Inc
- trebananib (AMG 386) / Amgen, Avastin (bevacizumab) / Roche
Enrollment closed: Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors (clinicaltrials.gov) - Sep 5, 2014
P2, N=141, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=47 --> 70 Recruiting --> Active, not recruiting
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial completion, Trial primary completion date: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Sep 5, 2014
P2, N=38, Completed, Sponsor: Italian Sarcoma Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Mar 2014
- veliparib (ABT-888) / AbbVie, Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, PARP Biomarker: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Sep 4, 2014
P1, N=96, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Mar 2014 Trial primary completion date: Jul 2014 --> Sep 2020
- Avastin (bevacizumab) / Roche
Phase classification, Enrollment change, Trial primary completion date: Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma (clinicaltrials.gov) - Sep 4, 2014
P2, N=7, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> Sep 2020 Phase classification: P3 --> P2 | N=78 --> 7 | Trial primary completion date: Aug 2008 --> Aug 2009
- Yeliva (opaganib) / Apogee Biotech, RedHill
New P1/2 trial: Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma (clinicaltrials.gov) - Sep 4, 2014
P1/2, N=33, Not yet recruiting, Sponsor: Apogee Biotechnology Corporation
- tasadenoturev (DNX-2401) / DNAtrix
Enrollment open: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Sep 4, 2014
P1, N=24, Recruiting, Sponsor: DNAtrix, Inc.
Phase classification: P3 --> P2 | N=78 --> 7 | Trial primary completion date: Aug 2008 --> Aug 2009 Not yet recruiting --> Recruiting
- ||| Endostar (recombinant human endostatin) / Simcere
Enrollment closed: A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma (clinicaltrials.gov) - Sep 4, 2014
P2, N=160, Active, not recruiting, Sponsor: Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | imatinib / Generic mfg.
Trial completion: Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma (clinicaltrials.gov) - Sep 3, 2014
P2, N=30, Completed, Sponsor: AIDS Malignancy Clinical Trials Consortium
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- carboplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date: Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov) - Aug 29, 2014
P2, N=65, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Oct 2015
- Trial termination, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Aug 29, 2014
P2, N=7, Terminated, Sponsor: City of Hope Medical Center
Trial primary completion date: Oct 2014 --> Oct 2015 Completed --> Terminated; The study was terminated prematurely due to withdrawal of support by the sponsor.
- Enrollment change, Trial termination, Surgery: Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Aug 29, 2014
P2, N=8, Terminated, Sponsor: Michael Vogelbaum, MD, PhD
Completed --> Terminated; The study was terminated prematurely due to withdrawal of support by the sponsor. N=40 --> 8 | Recruiting --> Terminated; Drugs unavailable
- H1299 cell lysate with iscomatrix adjuvant vaccine / National Cancer Institute
Enrollment closed, IO biomarker: Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (clinicaltrials.gov) - Aug 29, 2014
P1/2, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 8 | Recruiting --> Terminated; Drugs unavailable Recruiting --> Active, not recruiting
- Zarnestra (tipifarnib) / Kura Oncology
New P1 trial: Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Aug 28, 2014
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Trial completion: Valproic Acid in Treating Patients With Kaposi's Sarcoma (clinicaltrials.gov) - Aug 27, 2014
P=N/A, N=19, Completed, Sponsor: AIDS Malignancy Clinical Trials Consortium
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | semaxanib (SU5416) / Pfizer
Trial completion: SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma (clinicaltrials.gov) - Aug 27, 2014
P2, N=0, Completed, Sponsor: AIDS Malignancy Clinical Trials Consortium
Active, not recruiting --> Completed Not yet recruiting --> Completed
- || Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: A Study of Olaratumab in Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 26, 2014
P1/2, N=146, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Completed Trial primary completion date: Mar 2014 --> Aug 2014
- Enrollment change: ProAcTyon: Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria (clinicaltrials.gov) - Aug 25, 2014
P=N/A, N=134, Active, not recruiting, Sponsor: Centre Oscar Lambret
Trial primary completion date: Mar 2014 --> Aug 2014 N=200 --> 134
- | Avastin (bevacizumab) / Roche, rilotumumab (AMG 102) / Amgen
Enrollment closed: AMG 102 and Avastin for Recurrent Malignant Glioma (clinicaltrials.gov) - Aug 25, 2014
P2, N=36, Active, not recruiting, Sponsor: Katy Peters
N=200 --> 134 Recruiting --> Active, not recruiting
- | doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial initiation date, Surgery: GOG study : Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery (clinicaltrials.gov) - Aug 23, 2014
P3, N=216, Ongoing, Sponsor: EORTC
Recruiting --> Active, not recruiting Initiation date: Jun 2012 --> Mar 2013